NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Supreme Court Of India
    Central Bureau Of Investigation (CBI)
    Indian Army
    Indian Railways
    Indian Air Force
    NewsBytes
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Now, Bharat Biotech seeks emergency use approval for COVAXIN
    India

    Now, Bharat Biotech seeks emergency use approval for COVAXIN

    Now, Bharat Biotech seeks emergency use approval for COVAXIN
    Written by Shalini Ojha
    Dec 08, 2020, 12:14 pm 2 min read
    Now, Bharat Biotech seeks emergency use approval for COVAXIN

    After US-based Pfizer and Pune's Serum Institute of India, Bharat Biotech has sought an emergency use approval for its coronavirus vaccine, named COVAXIN. The vaccine is being developed indigenously by the Hyderabad-based company and the Indian Council of Medical Research (ICMR), the top government body leading the fight against coronavirus. The vaccine is currently in phase three trials. Here's more.

    Countries are giving approvals considering the unprecedented situation

    As per reports, an application regarding the same has been sent to the Drugs Controller General of India (DCGI). If granted permission, doses of the vaccine will be given to a select group of people. Such approvals are rare in nature, but countries have been going ahead with it considering the intensity of the pandemic. Till now, 1,550,263 have died worldwide.

    Bharat Biotech submitted its application on Monday

    "This (Bharat Biotech's) is an application (under the category of) issue of permission to either import, manufacture a drug or for grant of clinical trial NOC (no-objection certificate)," a person privy to developments told Indian Express.

    Expert panel will review the submissions of three companies tomorrow

    As three companies have sought emergency use authorization, the government has also framed the next steps. As per reports, an expert panel will review their submissions tomorrow. After thoroughly assessing the requests, the panel will share its findings with DCGI, which will then take a call. The approval will only be granted once authorities are confident that the vaccine is safe and effective.

    Earlier, minister, who was given COVAXIN, tested positive for coronavirus

    Notably, last week, Haryana's minister Anil Vij, who was administered a dose of COVAXIN in November, tested positive for COVID-19. Later, officials conducting trials refused to link Vij's infection with the vaccine, saying he was only given the first of the two doses needed. They argued that antibodies to protect someone from the disease are generated after the second dose, reports Indian Express.

    Meanwhile, India's coronavirus tally is nearing the one crore mark

    Disturbingly, India is the second worst-hit nation and is inching close to the one crore mark, as far as infections are concerned. At 9,703,908 total cases, the country has lost 140,994 to the contagious disease. This means citizens are desperately waiting for a vaccine. Last week, Prime Minister Narendra Modi assured India won't have to wait for long.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Latest
    Indian Council of Medical Research (ICMR)
    Coronavirus
    Serum Institute of India
    Bharat Biotech

    Latest

    #ViralVideo: AAP's Raghav Chadha reacts to Parineeti Chopra dating rumors  Bollywood Life
    Why is BYJU'S raising $250 million at a lower valuation BYJU'S
    Syria: Iranian drone attack kills US contractor; peace on edge Syria
    5 tourist mistakes to avoid on your trip to Belgium Belgium

    Indian Council of Medical Research (ICMR)

    H3N2: Experts advise caution as deaths and ICU admissions rise COVID-19
    H3N2: ICMR expert recommends influenza vaccine for low immunity people COVID-19
    H3N2 cases rise in India, experts say virus not life-threatening India
    Steep rise in H3N2, COVID-19 cases; masks, other measures return Randeep Guleria

    Coronavirus

    PM Modi to hold high-level meeting amid rising COVID-19 cases Narendra Modi
    India reports highest daily COVID-19 cases in 2023: Check tally COVID-19 India
    COVID-19 subvariant XBB 1.16 cases rise in India; guidelines revised COVID-19
    WHO lambasts China for allegedly hiding data on COVID-19's origin World Health Organization

    Serum Institute of India

    Serum Institute seeks DCGI's approval for Covovax as booster dose Drugs Controller General of India
    India's 100 richest amassed $25bn more wealth in 2022: Forbes Gautam Adani
    Covishield manufacturer SII duped of Rs. 1 crore, 7 arrested Pune
    Covishield death: Bombay HC notice to Centre, Serum Institute, DCGI Bombay High Court

    Bharat Biotech

    India's 1st nasal COVID-19 vaccine by Bharat Biotech launched COVID-19
    Bharat Biotech's iNCOVACC: Here's how much COVID-19 nasal vaccine costs COVID-19
    COVID-19 nasal vaccines are available but should you get one?  COVID-19
    COVID-19: Centre approves Bharat Biotech's nasal vaccine as booster dose Vaccine

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023